Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
68Ga satoreotide trizoxetan PET/CT in high-grade neuroendocrine lung cancer
2023-503362-24-01Phase 2Completed
- Sponsor
- Rigshospitalet
- Start
- May 2023
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of 68Ga-satoreotide trizoxetan in small cell lung cancer (SCLC) and large cell neuroendocrine carcinoma (LCNEC), sponsored by Rigshospitalet. Primary endpoint: Lesion-level detectability with 68Ga satoreotide trizoxetan PET. Started May 2023; status: completed.
02
Drugs
68Ga-satoreotide trizoxetan
03
Conditions
small cell lung cancer (SCLC)large cell neuroendocrine carcinoma (LCNEC)
Beyond the preview
Go deeper on 2023-503362-24-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503362-24-01.